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Abstract
Background: Trypanosomosis caused by Trypanosoma congolense is a major constraint to animal health in sub-Saharan
Africa. Unfortunately, the treatment of the disease is impaired by the spread of drug resistance. Resistance to diminazene
aceturate (DA) in T. congolense is linked to a mutation modifying the functioning of a P2-type purine-transporter responsible
for the uptake of the drug. Our objective was to verify if the mutation was linked or not to drug pressure.
Methodology/Principal Findings: Thirty-four T. congolense isolates sampled from tsetse or wildlife were screened for the
DA-resistance linked mutation using DpnII-PCR-RFLP. The results showed 1 sensitive, 12 resistant and 21 mixed DpnII-PCR-
RFLP profiles. This suggests that the mutation is present on at least one allele of each of the 33 isolates. For twelve of the
isolates, a standard screening method in mice was used by (i) microscopic examination, (ii) trypanosome-specific 18S-PCR
after 2 months of observation and (iii) weekly trypanosome-specific 18S-PCR for 8 weeks. The results showed that all mice
remained microscopically trypanosome-positive after treatment with 5 mg/kg DA. With 10 and 20 mg/kg, 8.3% (n=72) and
0% (n=72) of the mice became parasitologically positive after treatment. However, in these latter groups the trypanosome-
specific 18S-PCR indicated a higher degree of trypanosome-positivity, i.e., with a unique test, 51.4% (n=72) and 38.9%
(n=72) and with the weekly tests 79.2% (n=24) and 66.7% (n=24) for 10 and 20 mg/kg respectively.
Conclusion/Significance: The widespread presence of the DA-resistance linked mutation in T. congolense isolated from
wildlife suggests that this mutation is favourable to parasite survival and/or its dissemination in the host population
independent from the presence of drug. After treatment with DA, those T. congolense isolates cause persisting low
parasitaemias even after complete elimination of the drug and with little impact on the host’s health.
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Introduction
Animal trypanosomosis is one of the major constraints to animal
health and production in sub-Saharan Africa and has a major
impact on people’s livelihoods. The annual estimated direct and
indirect losses due to the disease run into billions of dollars [1]. The
fight against the disease is either managed by the control of the
vector or of the parasite or a combination of both. However, in poor
rural communities, which are mostly affected by the disease, control
is mainly relying on the use of trypanocidal drugs [2]. The main
drugs used by livestock keepers are isometamidium chloride (ISM)
which has both curative and prophylactic effects and DA which has
only curative properties. These drugs have been in use for more
than half a century now. Geerts & Holmes [3] estimated that ,35
million doses of trypanocides are administered every year in sub-
Saharan Africa, with ISM, ethidium bromide and DA representing
40%, 26% and 33% respectively. Despite the high usage of these
veterinary trypanocides, the interest of pharmaceutical industries to
invest in research for developing new products remains low, leaving
farmers to rely on the existing drugs. Due to the privatization of
veterinary services in most parts of Africa, farmers have easy access
to these trypanocides and this has resulted in rampant misuse and
under-dosage of the medications, actions which have been blamed
for the emergence of trypanocidal drug resistance [4,5]. To date,
there are 18 countries in which trypanocidal drug resistance has
been reported [2] and more recently in Benin, Ghana and Togo
(Re ´seau d’e ´pide ´miosurveillance de la re ´sistance aux trypanocides et
aux acaricides en Afrique de l’Ouest – RESCAO, unpublished
data). However, most of these reports seem to be confined to areas
where the disease is endemic [6]. Whilst reports of the occurrence of
trypanocidal drug resistance are increasing, it is not really clear
whether this is due to a real increase of the trypanocide resistance
problem or just an increased interest by scientists [2]. However, a
reportby Delespaux et al.[7]of a five-fold increase inthe prevalence
of DA resistance over a seven year period in the Eastern Province of
Zambia, suggests that there is indeed an aggravation of the
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multiple drug resistance (to ISM and DA) [8] because this is
threatening the last stand to overcome drug resistance through
the use of the sanative pair. Here, the concept of the sanative pair
recommends the use of two trypanocides (e.g. DA and ISM)
unlikely to induce cross-resistance. The first drug is used until
resistant strains of trypanosomes appear and then, the second is
substituted and used until the resistant strains have disappeared
from cattle and tsetse [9]. DA uptake is predominantly driven by
a P2-type purine transporter (TbAT1) in T. brucei and a set of six
point mutations in this gene has been shown to be linked with
resistance to the veterinary drug DA [10]. However, Delespaux
et al. [11] found that in T. congolense as i n g l ep o i n tm u t a t i o ni na n
orthologous gene of the T. brucei P2-type purine transporter
(TcoAT1) was correlated to resistance to DA in that species. Such
genetic mutations conferring drug resistance in parasites are
thought to arise randomly and to spread out when the parasite
population is exposed to the drug because the mutation(s) is/are
conferring a selective advantage compared to the wild type
population [12]. Hastings [13] identified the following as some of
the important factors determining the rate of evolution of the
drug resistance in a parasite population: (i) the mutation rate from
wild type to resistant genotype, (ii) the level and pattern of drug
use and (iii) the parasitaemia within the host i.e. the number of
parasites exposed to the drug after the treatment of the host.
Genetic mutations can impair the fitness of parasites allowing a
higher survival in presence of drugs but a progressive elimination
in absence of drug pressure [14]. However, these mutations will
still persist in a parasite population at low frequencies governed
by the mutation-selection balance [15] with their proportion
determined by the relative fitness of the mutant versus the wild
type parasites [16]. Innate phenotypes resistant to DA and to
homidium were already reported in T. vivax and T. congolense
respectively [17,18]. The objective of this study was thus to
examine the prevalence of the mutation linked to DA resistance
in natural T. congolense populations that never were exposed to the
pressure of the drug, this prevalence being the result of the
balance between the mutation rate and the ecological fitness of
the mutated trypanosome.
Materials and Methods
Ethics statement
This is to certify that the experiments carried out at the Institute
of Tropical Medicine in the framework of this study were
approved by the Ethics Committee of the Institute of Tropical
Medicine and that the study was conducted adhering to the
institutional guidelines for animal husbandry. In Belgium,
protection of experimental animals is regulated by the Royal
Decision of 14 NOV 1993.
Study areas and isolation of trypanosomes
All the trypanosomes used in this study were isolated in
protected areas where game animals served as exclusive hosts for
the trypanosomes. The study areas were the South Luangwa
National Park in Zambia, Mana Pools National Park in Zimbabwe
and the Hluhluwe-Umfolozi Game Reserve in the South African
KwaZulu-Natal. In the South Luangwa National Park, tsetse flies
(Glossina morsitans morsitans and G. pallidipes) were trapped using
epsilon traps [19] and flies were dissected to determine their
infection status. The mouthparts of tsetse flies, infected with
trypanosomes in both the midgut and mouthparts, were injected
intraperitoneally (I.P.) in an immunosuppressed mouse (300 mg/
kg Cyclophosphamide, EndoxanH, Baxter S.A.). The inoculated
mice were then monitored for the development of a trypanosome
infection, with the parasitaemic blood collected from each positive
mouse considered as an isolate. In the Hluhluwe-Umfolozi Game
Reserve, isolation of the trypanosomes was completed from
buffaloes belonging to herds that were selected randomly for
tuberculosis testing. From each of the 132 buffaloes sampled, a
volume of 0.3 ml of jugular blood was injected IP in two mice. The
injected mice were then monitored for development of a
trypanosome infection, with the parasitaemic blood collected from
each positive mouse considered as an isolate. In the Mana Pools
National Park, tsetse flies (Glossina morsitans morsitans and G.
pallidipes) were trapped using epsilon traps [19] and flies were
dissected to determine their infection status [20]. The mouthparts
of those flies infected in both the midgut and mouthparts, were
collected and preserved in a buffer of 0.5 M guanidine chloride,
pH 8.
All 34 isolates that were collected belonged to the T. congolense
Savannah sub-group as determined by the trypanosome specific
18S-PCR-RFLP [21]. The median survival times of mice
inoculated with the isolates from Hluhluwe-Umfolozi Game
Reserve and from the South Luangwa National Park, without
treatment, are described by Van den Bossche et al [22].
DA resistance genetic profiling by DpnII-PCR-RFLP
DNA extraction was conducted for all the 34 strains collected.
For the isolates that were successfully grown in mice, blood from
one parasitaemic mouse was collected and trypanosome DNA
extracted using the GentraH extraction kit as according to
manufacturer’s recommendations. For those strains which were
preserved in guanidine storage buffer, the trypanosome DNA was
also extracted. Briefly, the mouthparts were removed from the
buffer into 100 ml of grinding buffer (80 mM NaCl, 160 mM
sucrose, 100 mM Tris-HCl pH 8.6, 60 mM EDTA and 0.5%
SDS) and incubated at 65uC for one hour, with shaking. The dried
pellet was then suspended in 40 ml of TE buffer and this was used
for DNA analysis.
The DpnII-PCR-RFLP was performed on the 34 isolates to
check for the presence of the mutation in the P2-type purine
transporter gene that is associated with resistance to DA [11]. The
PCR and analysis of the amplicon was done using the method
Author Summary
Trypanosomosis is responsible for the death of 3 million
heads of cattle yearly, with 50 million animals at risk in sub-
Saharan Africa. DA, a commonly used drug against the
disease, was marketed decades ago. Drug resistance is
reported in 21 African countries. A common argument
about the origin of drug resistance is the selection by the
drug of rare individuals that are naturally resistant and the
propagation of those individuals in the population
because of the competitive advantage they have when
exposed to drug. When the drug pressure decreases, the
wild-type individuals regain their supremacy. The principal
objective of this study was thus to estimate the prevalence
of trypanosomes resistant to DA in a population that was
never exposed to the drug. Our results showing a high
prevalence of drug resistance in environments free of any
drug pressure is thought provoking and suggests that
ceasing the use of DA will not allow for a return to a DA-
sensitive population of trypanosomes. Drug resistance in
animal trypanosomes thus present a pattern different from
what is observed with Plasmodium sp. (causative agent of
malaria) where a complete stoppage in the use of the
chloroquine allows for a return to drug sensitivity.
Drug Resistance in the Absence of Drugs
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amplification step. In brief, a standard PCR was conducted on
DNA samples using the following primers (Ade2F ATAAT-
CAAAGCTGCCATGGATGAAG and Ade2R GATGACTAA-
CAATATGCGGGCAAAG) and a Sigma thermocyclerH.
In vivo drug sensitivity testing (multi doses test in mice)
The method described by Eisler et al. [24] was used for
evaluating the sensitivity of the isolates to DA. The method was
slightly modified as follows: the 12 field isolates were tested at
doses of 20 and 10 mg/kg DA administered intraperitoneally.
Inoculation of the trypanosomes, monitoring of the infected mice
and interpretation of the results was done as described by Eisler
et al. [24]. Briefly, 10
5 trypanosomes were inoculated in each
mouse and treatment was administered 24 hours after inoculation.
For each of the 12 isolates, two groups of six mice were used for
each drug dosage and its control. An isolate was considered
resistant to a particular dose if at least two of the six mice in that
treatment group relapsed (assessed by microscopical examination).
At the end of the 60 days experimental period, tail blood from all
mice was spotted onto a WhatmanH Nr 4 filter paper and
examined using the trypanosome specific 18S-PCR [21] to detect
presence of trypanosomes that could not be detected by the
microscopical examination. Mice were euthanized at the end of
the examination period. A reference strain sensitive to DA (TRT8)
was added as quality control for the trypanocide used. This isolate
originates from cattle in the Eastern Province of Zambia and was
then cloned visually from a single trypanosome. It shows a T.
congolense savannah type profile with the trypanosome specific 18S-
PCR-RFLP and a DA-sensitive profile with DpnII-PCR-RFLP.
Monitoring trypanosome presence by PCR
To determine the presence of trypanosomes in mice treated
with DA at a dose of 10 or 20 mg/kg, blood samples of the mice
infected with the 4 different isolates (MF2, MF3, MF4, MF5 and
TRT8 as the sensitive control) were weekly spotted on a
WhatmanH Nr 4 filter paper for 8 weeks and examined by the
trypanosome specific 18S-PCR to detect the presence of
trypanosomes. Proportions of relapses were calculated on the
basis of 24 mice leaving the sensitive control (TRT8) out.
Degradation of trypanosomal DNA in vivo
Blood (1.4 ml) was collected from a highly parasitaemic mouse
(10
8 trypanosomes/ml blood) and DNA extraction was done using
a GentraH extraction kit for a final volume of 200 ml of DNA
solution. 100 ml of this solution was intravenously injected into
each of two mice. Tail blood was then collected on filter paper
30 min. and 1, 3, 6, 7, 13, 15, 16, 21 & 28 days after the injection
and examined by the trypanosome specific 18S-PCR to detect the
presence of trypanosome DNA.
Results
Six isolates were collected in the South Luangwa National Park,
6 in the Hluhluwe-Umfolozi Game Reserve and 22 from Mana
Pools National Park. One strain showed a sensitive DpnII-PCR-
RFLP profile, 12 showed a resistant profile whilst the remaining 21
showed a mixed profile. When a mixed profile is observed, a
heterozygous trypanosome population cannot be differentiated
from a mixture of homozygous sensitive and resistant trypano-
somes as the experimental material are isolates and not cloned
trypanosomes.
The results of the drug sensitivity tests in mice are summarized
in table 1. This was done only for the 12 isolates isolated from
South Luangwa National Park and Hluhluwe-imfolozi game
reserve since only those had been successfully grown in mice.
Using the methodology and criteria described by Eisler et al.
(2001) only one resistant isolate was identified in the group treated
with 10 mg/kg and none in the group treated with 20 mg/kg.
However, using the more sensitive trypanosome-specific 18S-PCR
once at the end of the observation period, more trypanosome-
positive mice were observed in these groups, with 51.4% (n=72)
and 38.9% (n=72) positive PCR results respectively. At a dose of
5 mg/kg, all mice relapsed based upon microscopic examination
as well as PCR.
When considering the weekly follow up, the parasitaemias of the
groups inoculated with the 4 isolates (MF2, MF3, MF4 & MF5)
were intermittent throughout the period of observation and the
cumulative amount of relapses was impressive with 79.2% (n=24)
and 66.7% (n=24) in the groups treated with 10 and 20 mg/kg
respectively. As an example, the results for the weekly evolution of
parasitaemia as determined by trypanosome specific 18S-PCR
post-treatment with 20 mg/kg DA are shown in table 2.
Finally, the DNA of trypanosomes, when injected intravenously
into mice, persisted in the blood for 14 days beyond which it was
no longer detectable by the trypanosome specific 18S-PCR.
Discussion
The high prevalence of the mutation in the genes coding for P2-
type purine transporters in T. congolense populations that were
never exposed to any drug pressure is thought provoking. The
correlation of this mutation with phenotypic resistance to DA is
largely demonstrated by the multi-dose sensitivity testing in mice
[25]. This high prevalence of the mutation conferring resistance to
DA was not expected in regions where the circulating trypano-
some populations were never exposed to any trypanocidal drug
Table 1. DpnII-PCR-RFLP-profiles of the different wild T.
congolense strains and their drug sensitivity status in infected
mice treated with 20 and 10 mg/kg diminazene (DA).
10 mg/kg DA 20 mg/kg DA
Strain Profile Mic. + PCR + Mic. + PCR +
MF 1 R 0/6* 5/6 0/6 1/6
MF 2 R 0/6 1/6 0/6 3/6
MF 3 R 5/6 6/6 0/6 1/6
MF 4 M 1/6 5/6 0/6 5/6
MF 5 R 0/6 1/6 0/6 2/6
MF 6 R 0/6 2/6 0/6 2/6
BT0106 M 0/6 4/6 0/6 5/6
BT0206 M 0/6 3/6 0/6 5/6
BT0306 M 0/6 3/6 0/6 3/6
BT0306 ISM R 0/6 4/6 0/6 3/6
BT0406 M 0/6 3/6 0/6 1/6
BT0506 R 0/6 0/6 0/6 1/6
TRT8 sensitive control S 0/6 0/6 0/6 0/6
CRS 8.33% 51.38% 0% 38.88%
This drug sensitivity status was scored for each individual mouse by microscopy
and trypanosome specific 18S-PCR analysis, 60 days after the initial treatment.
With R for resistant, M for mixed, S for sensitive, CRS for cumulative relapsing
rate and *for number of mice positive by the trypanosome specific 18S-PCR.
doi:10.1371/journal.pntd.0001454.t001
Drug Resistance in the Absence of Drugs
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related to a fitness cost for the parasite and are supposed to be
selected out in the absence of drug as it is described, for example,
in malaria parasites [14,15]. On the contrary, a complete stoppage
of the use of DA would not allow for a return to a DA-sensitive
population of trypanosomes.
The observed high prevalence of the DA-resistance linked
mutation (97.1%) in the wild T. congolense populations suggests that
it confers a selective advantage over the non-mutated strains and
that it is part of the normal genotypic diversity of a wild
trypanosome population. However, the observation of 97.1% of
mutated strains is in contrast with previous studies in Eastern
Province of Zambia reporting 38.5% of mutated strains in 1996.
Interestingly, without any change in the drug use this proportion
already raised to 89.5% seven years later, in 2004. This situation
and trend to an increasing percentage of the mutated strains might
be the result of the massive, systematic and widespread ISM block
treatments that were organized in the eighties by the Zambian
government in an attempt to eradicating trypanosomes from tsetse
flies [26]. This massive treatment campaign presumably resulted
in a severe genetic bottleneck in the existing T. congolense
population constituting mainly of non-mutated strains (for DA).
This scenario could have simply occurred by a random effect on
the selection. At the end of the massive drug pressure, we can
reasonably assume that the trypanosome population multiplied
again and that the percentage of mutated strains increased
gradually due to a fitness advantage of the mutated strains.
Albeit the microscopical examination failed to detect nearly all
relapses except after treatment at 5 mg/kg DA, the results of the
trypanosome specific 18S-PCR confirms unequivocally the
numerous relapses after treatment at 10 and 20 mg/kg. This
PCR-positivity is not due to persistent circulating trypanosomal
DNA as we demonstrated that injected DNA of trypanosomes is
no longer PCR-detectable in the mouse blood circulation 14 days
after the initial injection. This strongly suggests that the positive
PCR results observed in the microscopically negative mice
indicates the presence of living trypanosomes circulating at low
abundance. With a single examination at the end of the
observation period, more than one half and one third of the
isolates relapsed at 10 and 20 mg/kg respectively. Furthermore,
the weekly follow up of the parasitaemias shows clearly that the
increased frequency of observation after treatment (8 rather than 1
at the end of the observation period) raises the observed relapses
rate to 79.2% and 66.7% for 10 and 20 mg/kg respectively.
Remarkably, the positive outcome of the trypanosome specific
18S-PCR tests done two months after treatment compared to the
negative microscopical examinations suggests that the relapsed
trypanosome populations remain at very low densities. This is
surprising since it can be assumed that no active DA is circulating
in the blood two months after the treatment. Indeed, the
recommended withdrawal time prior slaughtering for livestock is
21–35 days and the elimination rate of DA is not expected to be
longer in rodents as it is a smaller species with a higher metabolism
[27,28]. This observation seems to suggest that the DA treatment
has reduced the impact of the relapsed trypanosome infection on
its host. This becomes evident when observing the median survival
time of the mice that are infected with the same isolates before DA
treatment [22]. Without treatment, 50% and 67% of the mice die
within 10 and 20 days respectively. The predicted median survival
time for the two less virulent isolates is 24 and 51 days. None of the
mice is expected to survive for 60 days as they manage in good
shape in our drug resistance test. The development of such cryptic
infections could be due to the effect of the drug reducing the
parasitaemia to a level low enough for host immunity to maintain
the parasites at a very low density. If this observation can be
confirmed in livestock, it would drastically change the rationale of
treatment guidelines in case of DA resistance.
Those very low parasitaemias with very limited impact on the
host induced by the DA treatment are interesting. Similar results
were obtained in cattle when experimentally infected with ISM
resistant strains and treated with ISM at the first peak of
parasitaemia. The impact of the infection on the PCV was not
very pronounced (average PCV reduction 8 to 14 weeks after
treatment: 5.9%; 95% CI: 4.5–7.3) [29].
Our findings have important repercussions for the understand-
ing of the epidemiology of trypanocidal drug resistance in livestock
trypanosomosis and its control: (i) considering the high prevalence
of the resistant genotype in the natural T.congolense isolates from
Zambia and South Africa, development of resistance to DA once
these strains are circulating in livestock seems to be unavoidable
and quick, (ii) regular under-dosing will support the spread of the
resistant wild genotypes in the livestock population [4,26] and
finally (iii) if our results are further confirmed in livestock, the
advice could be to continue treating cattle even in the presence of
drug resistance as the treatment would allow the host to control
the parasite and the corresponding disease at an acceptable level.
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